Class summary at a glance.

Every drug in the Plasma Kallikrein Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $384.0Mcombined across class
Total Rx claims: 8K1K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Lanadelumab-Flyo

Brand: TAKHZYRO · 7K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2018-08-24

Brand-only (no generics) 84 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $352.9M

Class share

92%

of class CY24 spend

View profile →

Ecallantide

Brand: Kalbitor · 422 Part D claims (CY24) · 62 beneficiaries · First FDA approval: 2010-02-02

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $31.1M

Class share

of class CY24 spend

View profile →

Sebetralstat

Brand: EKTERLY · — Part D claims (CY24) · First FDA approval: 2025-07-07

Brand-only (no generics) 3 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.